Design and synthesis of phosphotyrosine peptidomimetic prodrugs

Journal of Medicinal Chemistry

Volumn 49, Issue 11, 2006, Pages 3368-3376

  Garrido Hernandez, Hugo ^a   Moon, Kyung D ^a   Geahlen, Robert L ^a   Borch, Richard F ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N METHYL N (4 CHLOROBUTYL) O (5 NITROFURYL 2 METHYL) O (4 (1 (3 CARBAMOYL 4 CYCLOHEXYLMETHOXYPHENYL)ETHYLCARBAMOYL)) PHENYL PHOSPHORODIAMIDATE; N METHYL N (4 CHLOROBUTYL) O (5 NITROFURYL 2 METHYL) O [1 (3 CARBAMOYL 4 CYCLOHEXYLMETHOXYPHENYL)METHYL]PHENYL PHOSPHORAMIDATE; N METHYL N (4 CHLOROBUTYL) O (5 NITROFURYL 2 METHYL) O [4 [1 (3 CARBAMOYL 4 CYCLOHEXYLMETHOXYPHENYL)ETHYLCARBAMOYL]]PHENYL PHOSPHORAMIDATE; N METHYL N (4 CHLOROBUTYL) O (5 NITROFURYL 2 METHYL) O [4 [1 (3 CARBAMOYL 4 CYCLOHEXYLMETHOXYPHENYL)ETHYLCARBAMOYL]METHYL]PHENYL PHOSPHORODIAMIDATE; N METHYL N (4 CHLOROBUTYL) O (5 NITROFURYL 2 METHYL) O [4 [2 [ACETYLAMINO 2 [1 (3 CARBAMOYL 4 CYCLOHEXYLMETHOXYPHENYL)ETHYLCARBAMOYL]ETHYL]]]PHENYL PHOSPHORODIAMIDATE; N METHYL N (4 CHLOROBUTYL) O (5 NITROFURYL 2 METHYL) O [4 [2 ACETYLAMINO 2 [1 (3 CARBAMOYL 4 CYCLOHEXYLMETHOXYPHENYL)ETHYLCARBAMOYL]ETHYL]]PHENYL PHOSPHORAMIDATE; PEPTIDOMIMETIC; PHOSPHATE; PHOSPHORODIAMIDATE DERIVATIVE; PHOSPHOTYROSINE; PRODRUG; PROTEIN SH2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIZATION; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; PROTEIN TARGETING; REDUCTION; STRUCTURE ANALYSIS;

AMIDES; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; DRUG DESIGN; HUMANS; HYDROLYSIS; JURKAT CELLS; KINETICS; MOLECULAR MIMICRY; PEPTIDES; PHOSPHORIC ACID ESTERS; PHOSPHORIC ACIDS; PHOSPHOTYROSINE; PRODRUGS; SRC HOMOLOGY DOMAINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33744786265     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060142p     Document Type: Article

References (31)

1. Koch, C. A.; Anderson, D.; Moran, M. F.; Ellis, C.; Pawson, T. SH2 and SH3 Domains: Elements that Control Interactions of Cytoplasmic Signaling Proteins. Science 1991, 252, 668-74.
2. Beattie, J. SH2 Domain Protein Interaction and Possibilities for Pharmacological Intervention. Cell. Signalling 1996, 8, 75-86.
3. Songyang, Z.; Shoelson, S. E.; Chaudhuri, M.; Gish, G.; Pawson, T.; Haser, W. G.; King, F.; Roberts, T.; Ratnofsky, S.; Lechleider, R. J.; Nell, B. G.; Birge, R. B.; Fajardo, J. E.; Chou, M. M.; Hanafusa, H.; Schafhausen, B.; Cantley, L. C. SH2 Domains Recognize Specific Phosphopeptide Seqeunces. Cell 1993, 72, 767-778.
4. Songyang, Z.; Shoelson, S. E.; McGlade, J.; Oliver, P.; Pawson, T.; Bustelo, X. R.; Barbacid, M.; Sabe, H.; Hanafusa, H.; Yi, T.; Ren, R.; Baltimore, D.; Ratnosky, S.; Feldman, R. A.; Cantley, L. C. Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, Fps/Fes, GRB-2, HCP, SHC, Syk and Vav. Mol. Cell. Biol. 1994, 14, 2777-2785.
5. c-src with Two Major Signaling Pathways in Human Breast Cancer. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 83-7.
6. c-src Protein Kinase is an Early Event in Colonic Carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 558-62.
7. Ottenhoff-Kalff, A. E.; Rijsken, G.; van Beurden, E. A. C. M.; Hennipman, A.; Michles, A. A.; Staal, G. E. J. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res. 1992, 52, 4773-8.
8. Lewis, L. A.; Chung, C. D.; Chen, J. P. J. R.; Moran, M.; Patel, V. P.; Miceli, M. C. The Lck SH2 Phosphotyrosine Binding Site Is Critical for Efficient TCR-Induced Procesive Tyrosine Phosphorylation of the ζ-Chain and IL-2 Production. J. Immunol. 1997, 159, 2292-300.
9. Sawyer T. K. Src homology-2 domains: Structure, mechanisms, and drug discovery. Biopolymers 1998, 47, 243-61.
10. Lee, T.; Lawrence, D. S. Nonpeptidic ligands that target the SH2 domain of the lck tyrosine kinase. J. Med. Chem. 2000, 43, 1173-9.
11. Beaulieu, P. L.; Cameron, D. R.; Ferland, J.-M.; Gauthier, J.; Ghiro, E.; Gillard, J.; Gorys, V.; Poirier, M.; Rancourt, J.; Wernic, D.; Llinas-Brunet, M.; Betageri, R.; Cardozo, M.; Hickey, E. R.; Ingraham, R.; Jakes, S.; Kabcenell, A.; Kirrane, T.; Lukas, S.; Patel, U.; Proudfoot, J.; Sharma, R.; Tong, L.; Moss, N. Ligands for the tyrosine kinase p56lck SH2 domain: Discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements. J. Med. Chem. 1999, 42, 1757-66.
12. Proudfoot, J. R.; Betageri, R.; Cardozo, M.; Gilmore, T. A.; Glynn, S.; Hickey, E. R.; Jakes, S.; Kabcenell, A.; Kirrane, T. M.; Tibolla, A. K.; Lukas, S.; Patel, U. R.; Sharma, R.; Yazdanian, M.; Moss, N. Nonpeptidic, Monocharged, Cell Permeable Ligands for the p56Lck SH2 Domain. J. Med. Chem. 2001, 44, 2421-31.
13. Bohacek, R.; Dalgarno, D. C.; Hatada, M.; Jacobsen, V. A.; Lynch, B. a.; Macek, K. J.; Merry, T.; Metcalf, C. A. I.; Narula, S. S.; Sawyer, T. K.; Shakespeare, W. C.; Violette, S. M.; Weigele, M. X-ray Structure of Citrate Bound to Src SH2 Leads to a High-Affinity. Bone-Targeted Src SH2 Inhibitor. J. Med. Chem. 2001, 660-3.
14. Fu, J.-M.; Castelhano, A. L. Design and Synthesis of a Pyridone-Based Phosphotyrosine Mimetic. Bioorg. Med. Chem. Lett. 1998, 8, 2813-6.
15. Mathe, C.; Periguad, C.; Gosselin, G.; Imbach, J. L. Phosphopeptide Prodrug Bearing an S-Acyl-2-thioethyl Enzyme-Labile Phosphate Protection. J. Org. Chem. 1998, 63, 8547-50.
16. Meyers, C. L. F.; Hong, L.; Joswig, C.; Borch, R. F. Synthesis and biological activity of novel 5-fluoro-2′-deoxyuridine phosphoramidate prodrugs. J. Med. Chem. 2000, 43, 4313-8.
17. Tobias, S. C.; Borch, R. F. Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs. J. Med. Chem. 2001, 44, 4475-80.
18. Tobias, S. C.; Borch, R. F. Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol. Pharm. 2004, 1, 112-6.
19. Fries, K. M.; Joswig, C.; Borch, R. F. Synthesis and biological evaluation of 5-fluoro-2′-deoxyuridine phosphoramidate analogues. J. Med. Chem. 1995, 38, 2672-80.
20. Freel Meyers, C. L.; Borch, R. F. Activation mechanisms of nucleoside phosphoramidate prodrugs. J. Med. Chem. 2000, 43, 4319-27.
21. Lunney, E. A.; Para, K. S.; Rubin, J. R.; Humblet, C.; Fergus, J. H.; Marks, J. S.; Sawyer, T. K. Structure-based design of a novel series of nonpeptide ligands that bind to the pp60src SH2 domain. J. Am. Chem. Soc. 1997, 119, 12471-6.
22. Steinberg, G.; Borch, R. F. Synthesis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidates as folate receptor-targeted alkylating agents. J. Med. Chem. 2001, 44, 69-73.
23. Alsina, J.; Rabanal, F.; Chiva, C.; Giralt, E.; Albericio, F. Active Carbonate Resins: Application to the Solid-Phase Synthesis of Alcohol, Carbamate and Cyclic Peptides. Tetrahedron 1998, 54, 10125-52.
24. Smyth, M. S.; Ford, H.; Burke, T. R. A General Method for the Preparation of Benzylic α, α-Difluorophosphonic Acids; Non-Hydrolyzable Mimetics of Phosphotyrosine. Tetrahedron Lett. 1992, 33, 4137-40.
25. Domchek, S. M.; Auger, K. R.; Chatterjee, S.; Burke, T. R. Jr; Shoelson, S. E. Inhibition of SH2 domain/phosphoprotein association by a nonhydrolyzable phosphonopeptide. Biochemistry 1992, 31, 9865-70.
26. Gamcsik, M. P.; Ludeman, S. M.; Shulman-Roskes, E. M.; McLennan, I. J.; Colvin, M. E.; Colvin, O. M. Protonation of phosphoramide mustard and other phosphoramides. J. Med. Chem. 1993, 36, 3636-45.
27. Millis, K. K.; Colvin, M. E.; Shulman-Roskes, E. M.; Ludeman, S. M.; Colvin, O. M.; Gamcsik, M. P. Comparison of the Protonation of Isophosphoramide Mustard and Phosphoramide Mustard. J. Med. Chem. 1995, 38, 2166-75.
28. Hiroi, K.; Abe, J.; Suya, K.; Sato, S.; Koyama, T. The Palladium-Catalyzed Asymmetric α-Allylation of Carbonyl Compounds with Chiral Allyl Esters via Enamines and Imines. J. Org. Chem. 1994, 59, 203-13.
29. Straus, D. B.; Chan, A. C.; Patai, B.; Weiss, A. SH2 domain function is essential for the role of the Lck tyrosine kinase in T cell receptor signal transduction. J. Biol. Chem. 1996, 271, 9976-81.
30. Won, J.; Hur, Y. G.; Hur, E. M.; Park, S. H.; Kang, M. A.; Choi, Y.; Park, C.; Lee, K. H.; Yun, Y. Rosmarinic acid inhibits TCR-induced T cell activation and proliferation in an Lck-dependent manner. Eur. J. Immunol. 2003, 33, 870-9.
31. Hanke, J. H.; Gardner, J. P.; Dow. R. L.; Changelain, P. S.; Brissette, W. H.; Weringer, E. J.; Pollok, B. A.; Connely, P. A. Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor. J. Biol. Chem. 1996, 271, 695-701.